Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Monitoring circulating tumor cells (CTC) has been shown to be prognostic in most solid malignancies. There is no CTC assay in clinical use for lung cancer therapy monitoring due to inconclusive clinical utility data. Limited data has been published outside of the standard CTC enumerations, regarding clinical significance of phenotypic heterogeneity of CTCs in late stage NSCLC and its ability to correlate with treatment outcomes. METHODS: In 81 patients with stage IV NSCLC, multiple timepoints for CTC analysis were collected after initiation of treatment across 139 lines of therapy using single cell high definition diagnostic pathology imaging of all nucleated cells from 362 peripheral blood samples as a liquid biopsy. RESULTS: We analyzed the subset of 25 patients with complete time series data, totaling 117 blood samples, to determine the significance of HD-CTC kinetics during the initiation of treatment. These kinetics follow three distinct patterns: an increase in HD-CTCs with therapy (mean + 118.40 HD-CTCs/mL), unchanged HD-CTCs numbers (stable; mean 0.54 HD-CTCs/mL), and a decrease in HD-CTCs numbers (mean - 81.40 HD-CTCs/mL). Patients with an increasing CTC count during the first 3 months post initiation of new treatment had a better PFS and OS compared to the other groups. There was weak correlation between the absolute number of HD-CTCs at a single time point of therapy and patient outcomes (OS p value = 0.0754). In the whole cohort of 81 patients, HD-CTCs were detected in 51 (63%) patients at initiation of therapy with a median of 2.20 (range 0-509.20) and a mean of 26.21 HD-CTCs/mL (± 15.64). CONCLUSIONS: CTCs are identifiable in most patients with stage IV NSCLC. While absolute HD-CTC counts do not correlate with prognosis, the changes in CTC counts were predictive of survival in patients with metastatic lung cancer receiving chemotherapy. The level and dynamics of CTCs indicate very different biological and pharmacological phenomena at different stages of disease and timepoints of treatment, highlighting the complex role of CTCs in cancer research and clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The implication of CTCs is well established in tumor cell dormancy, as a major cause of metastatic outgrowth, multi drug resistance (MDR) and cancer relapse [144].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [144]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,841
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. W. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,030
Krebs, M. G., Sloane, R., Priest, L., Lancashire, L., Hou, J.-M., Greystoke, A., Ward, T. H., Ferraldeschi, R., Hughes, A., Clack, G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7045 · Cited by 868
Frequent EpCam protein expression in human carcinomas
Went, P. T. H., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., & Dirnhofer, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.08.026 · Cited by 819
Isolation and retrieval of circulating tumor cells using centrifugal forces
Hou, H. W., Warkiani, M. E., Khoo, B. L., Li, Z. R., Soo, R. A., Tan, D. S.-W., Lim, W.-T., Han, J., Bhagat, A. A. S., & Lim, C. T. (2013) · Scientific Reports · doi:10.1038/srep01259 · Cited by 736
Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., Johnson, A., Jendrisak, A., Bambury, R., Danila, D., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1828 · Cited by 641
Size-selective collection of circulating tumor cells using Vortex technology
Sollier, E., Go, D. E., Che, J., Gossett, D. R., O'Byrne, S., Weaver, W. M., Kummer, N., Rettig, M., Goldman, J., Nickols, N., et al. (2014) · Lab Chip · doi:10.1039/c3lc50689d · Cited by 498
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“The implication of CTCs is well established in tumor cell dormancy, as a major cause of metastatic outgrowth, multi drug resistance (MDR) and cancer relapse [144] .”
BackgroundBui, T. M., Wiesolek, H. L., & Sumagin, R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mr0220-549r · Cited by 957
Zeinali, M., Lee, M. C., Nadhan, A., Mathur, A., Hedman, C., Lin, E., Harouaka, R. A., Wicha, M. S., Zhao, L., Palanisamy, N., et al. (2020) · Cancers · doi:10.3390/cancers12010127 · Cited by 96
Label-free detection of rare circulating tumor cells by image analysis and machine learning
Wang, S., Zhou, Y., Qin, X., Nair, S., Huang, X., & Liu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-69056-1 · Cited by 84
Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’?
Visal, T. H., den Hollander, P., Cristofanilli, M., & Mani, S. A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01768-9 · Cited by 78
Metadata
- Authors
- Shishido, S. N., Carlsson, A., Nieva, J., Bethel, K., Hicks, J. B., Bazhenova, L., & Kuhn, P.
- Affiliations
- University of Southern California (US)
- Scripps Clinic (US)
- University of California San Diego (US)
- Venue
- Journal of Translational Medicine
- Published
- 2019-08-28
- Volume
- 17
- Issue
- 1
- Pages
- 294-294
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC6714097
- OpenAlex
- W2970445176
- Cited by
- 64
- References
- 53
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 18 · 2021: 9 · 2020: 15
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (U54CA143906, P30CA014089)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- circulating tumor cells, non-small cell lung cancer, stage IV lung cancer, liquid biopsy, treatment response monitoring, prognostic factors, progression-free survival, overall survival, chemotherapy, metastatic lung cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Kinetics, Lung Neoplasms, Male, Middle Aged, Neoplastic Cells, Circulating, Neoplasm Staging, Cohort Studies, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. https://app.cochat.ai/papers/10.1186/s12967-019-2035-8
- The paper
- Shishido, S. N., Carlsson, A., Nieva, J., Bethel, K., Hicks, J. B., Bazhenova, L., & Kuhn, P. (2019). Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-019-2035-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.